AstraZeneca acquires neuroscience assets from Link Medicine

Friday, July 13, 2012 03:20 PM

AstraZeneca has acquired a portfolio of neuroscience assets from Link Medicine, a privately held biopharmaceutical company based in Massachusetts. Link Medicine has focused its R&D efforts in the field of autophagy, an intracellular process that clears and recycles misfolded proteins, and has been developing potential new treatments for a range of neurodegenerative diseases.

AstraZeneca acquired multiple small molecule assets in clinical and preclinical stages that target the enzyme farnesyltransferase and modulate autophagy. Autophagy is an emerging area of research that can be applied to a range of neurodegenerative diseases, including Parkinson's and Alzheimer's disease, both of which are characterized by a build-up of incorrectly folded, aggregated and ultimately neurotoxic proteins.

The agreement is the third for AstraZeneca's new neuroscience Innovative Medicines Unit, established earlier this year. Under this new model, AstraZeneca is continuing to invest in neuroscience discovery research and early development for small and large molecules by tapping into the best available external science.

AstraZeneca will make specified upfront and milestone payments and will assume all of the program's R&D activities.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 15

WIRB-Copernicus Group acquires New England IRB

BBK Worldwide secures $3 million in private á¼€nancingto accelerate its global and technological expansion

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs